A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.

Kristen R Spencer,Daniella E Portal,Joseph Aisner,Mark N Stein,Jyoti Malhotra,Weichung Shih,Nancy Chan,Ann W Silk,Shridar Ganesan,Susan Goodin,Murugesan Gounder,Hongxia Lin,Jiadong Li,Robert Cerchio,Christina Marinaro,Suzie Chen,Janice M Mehnert

Oncotarget（2023）

引用 1|浏览33

暂无评分

摘要

Combination therapy with riluzole and sorafenib was safe and tolerable in patients with advanced solid tumors. The partial response in a patient with a RAF1 fusion suggests that further exploration in a genomically selected cohort may be warranted.

查看译文

关键词

GRM1,clinical trial,phase I,riluzole,sorafenib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要